Charles River Supports the National Cancer Institute and Establishes New RMS Operations
July 29 2008 - 9:00AM
Business Wire
In response to increasing demand and to better serve its customer
the National Cancer Institute (NCI), Charles River Laboratories
International, Inc. (NYSE: CRL) today announced the opening of its
52,000 square foot Frederick, Maryland facility. In the new
facility, Charles River is working side by side with NCI in a
seamless partnership to produce the highest quality research models
available. �In 2008, more than 1.4 million people will be diagnosed
with cancer. This translates into one person every 22 seconds,
every day this year, being told they have cancer,� said Dr. Melinda
Hollingshead, Chief of the Biological Testing Branch at The
National Cancer Institute-Frederick. �Because Charles River built
this facility for us, we are able to invest in the research and
development of new therapeutics for patients who need them. By
partnering with them, we gain an experienced, high-quality service
provider who helps us accelerate our drug development efforts.�
Building our clients� facilities for them The new facility employs
approximately 120 employees, 80 of whom are focused on providing
genetically defined, pathogen-free mice to support NCI/NIH
(National Institutes of Health)-funded research targeting the
causes and treatments of infectious and metabolic diseases, cancer
and other nationally recognized health issues. In addition, Charles
River has assumed responsibility for the management of the NCI/NIH
Tumor and Natural Products Repository, which stores a wide array of
tumor samples under carefully controlled conditions so that they
can be made available to researchers who are exploring the causes
and treatment of cancer. The half of the shared facility dedicated
to supporting NCI will be staffed and operated by Charles River�s
Consulting and Staffing Services (CSS) group. CSS offers
recruitment, training, staffing and management services to
customers at their sites or in Charles River facilities. The other
half of the facility will be occupied by Charles River�s Research
Models and Services (RMS) business, which will use this new space
as a platform for growth in the Baltimore/Washington geographic
market. �Our new Frederick facility is more than just a building
that produces the finest research models available globally. This
shared-space facility symbolizes the evolving dynamics in the drug
development process, as we truly become one with our customers,�
said James C. Foster, Chairman, President and Chief Executive
Officer of Charles River. �Our investment in this state-of-the-art
facility coupled with our core competencies of veterinary medicine
and science enable us to help accelerate NCI�s drug development
programs.� Charles River announced the details of its relationship
with NCI on September 22, 2006, �Charles River Laboratories Awarded
$111.6 Million National Cancer Institute Contract; Charles River to
Construct New Facility in Support of NCI and RMS Geographic
Expansion.� The following press release outlines the details of
this agreement.
http://ir.criver.com/phoenix.zhtml?c=121668&p=irol-newsArticle&ID=
908299&highlight (Due to the length of this URL, it may be
necessary to copy and paste it into your Internet browser's URL
address field. You may also need to remove an extra space in the
URL if one exists.) About Charles River Accelerating Drug
Development. Exactly. Charles River provides essential products and
services to help pharmaceutical and biotechnology companies,
government agencies, and leading academic institutions around the
globe accelerate their research and drug development efforts.�Our
more than 8,500 employees worldwide are focused on providing
clients with exactly what they need to improve and expedite the
discovery, development through first-in-human evaluation, and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Jul 2023 to Jul 2024